A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3540378 IN ADULTS WITH WORSENING CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
- Registry ID
- J3E-MC-EZDB
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2023-03-17
- Last update
- 2022-09-09
Conditions
- CHRONIC HEART FAILURE
- HEART FAILURE WITH PRESERVED EJECTION FRACTION
Related clinical trials
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF MARIDEBART CAFRAGLUTIDE ON MORTALITY AND
MORBIDITY IN PARTICIPANTS LIVING WITH HEART FAILURE WITH PRESERVED OR
MILDLY REDUCED EJECTION FRACTION AND OBESITY (MARITIME-HF)
- EASI-HF REDUCED - A PHASE III DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP
SUPERIORITY TRIAL TO EVALUATE EFFICACY AND SAFETY OF THE COMBINED USE OF ORAL
VICADROSTAT (BI 690517) AND EMPAGLIFLOZIN COMPARED WITH PLACEBO AND
EMPAGLIFLOZIN IN PARTICIPANTS WITH SYMPTOMATIC CHRONIC HEART FAILURE (HF: NYHA
II-IV) AND LEFT VENTRICULAR EJECTION FRACTION (LVEF) < 40%
- A PHASE III, RANDOMISED, OPEN-LABEL, BLINDED ENDPOINT, COMPARATIVE TRIAL OF
FERRIC DERISOMALTOSE VERSUS NO INTRAVENOUS IRON IN IRON-DEFICIENT SUBJECTS WITH
SYMPTOMATIC CHRONIC HEART FAILURE
- PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY AND
EFFICACY STUDY OF CDR132L ON REVERSE CARDIAC REMODELLING IN PARTICIPANTS WITH
HEART FAILURE WITH PRESERVED EJECTION FRACTION AND LEFT VENTRICULAR HYPERTROPHY
- A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE
SAFETY AND EFFICACY OF JK07 IN ADULTS WITH CHRONIC HEART FAILURE (RENEU-HF)
- A PHASE III, RANDOMISED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BALCINRENONE/DAPAGLIFLOZIN, COMPARED WITH DAPAGLIFLOZIN, ON THE RISK OF HEART FAILURE EVENTS AND CARDIOVASCULAR DEATH IN PATIENTS WITH HEART FAILURE AND IMPAIRED KIDNEY FUNCTION
View on source registry